Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.

Neil D. Theise, Anthony R. Arment, Dimple Chakravarty, John M.H. Gregg, Ira M. Jacobson, Kie Hoon Jung, Sujit S. Nair, Ashutosh K. Tewari, Archie W. Thurston, John Van Drie, Jonna B. Westover

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

PT150 is a clinical-stage molecule, taken orally, with a strong safety profile having completed Phase 1 and Phase 2 clinical trials for its original use as an antidepressant. It has an active IND for COVID-19. Antiviral activities have been found for PT150 and other members of its class in a variety of virus families; thus, it was now tested against SARS-CoV-2 in human bronchial epithelial lining cells and showed effective 90% inhibitory antiviral concentration (EC90) of 5.55 µM. PT150 is a member of an extended platform of novel glucocorticoid receptor (GR) and androgen receptor (AR) modulating molecules. In vivo, their predominant net effect is one of systemic glucocorticoid antagonism, but they also show direct downregulation of AR and minor GR agonism at the cellular level. We hypothesize that anti-SARS-CoV-2 activity depends in part on this AR downregulation through diminished TMPRSS2 expression and modulation of ACE2 activity. Given that hypercortisolemia is now suggested to be a significant co-factor for COVID-19 progression, we also postulate an additive role for its potent immunomodulatory effects through systemic antagonism of cortisol.

Original languageEnglish
Pages (from-to)3632-3638
Number of pages7
JournalCell Cycle
Volume19
Issue number24
DOIs
StatePublished - 2020

Keywords

  • Androgen receptor
  • COVID-19
  • Glucocorticoid antagonist
  • SARS-CoV-2
  • Therapeutic

Fingerprint

Dive into the research topics of 'Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.'. Together they form a unique fingerprint.

Cite this